Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Opthea parts with CEO, lays off over 80% of company
(Image Credit: AdobeStock/Andrii Yalanskyi) Opthea has released a corporate update following its settlement of the Development Funding Agreement (“DFA”) with the 2 investors under the DFA.1 The company previously provided an update in April 20252 stating its intention to lay…
FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
(Image Credit: AdobeStock/Corona Borealis) The US Food and Drug Administration (FDA) has accepted Opus Genetics’ Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal disease (IRD). Best disease, or vitelliform macular…
Study establishes reference data set for geographic atrophy lesion progression
(Image Credit: AdobeStock/tadamichi) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science &…
First time results of VOY-101 for geographic atrophy
Omer Trivizki, MD, MBA, at the 2025 ASRS meeting Omer Trivizki, MD, MBA, Deputy Chair working in Tel Aviv Medical Center presented, “First time results of VOY-101, a novel, complement-modulating gene therapy for geographic atrophy.” This presentation was given at…
First patients dosed in JC02-88 study
(Image credit: ©Alernon77/AdobeStock) jCyte recently announced the dosing of the first patients enrolled in the JC02-88 study for the evaluation of famzeretcel (jCell; jCyte) for the treatment of retinitis pigmentosa (RP).1 Famzeretcel consists of allogeneic retinal progenitor cells (RPCs) administered…
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
Infographic: landmark trials in neuro-ophthalmology – results of the REVERSE trial for unilateral gene therapy rAAV2/2-ND4 in leber hereditary optic neuropathy – Nature
Infographic: landmark trials in neuro-ophthalmology – results of the REVERSE trial for unilateral gene therapy rAAV2/2-ND4 in leber hereditary optic neuropathy Nature Source: Author: | Date: 2025-07-16 07:00:00 Source: Author: | Date: 2025-07-16 07:00:00
Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial | Eye – Nature
Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial | Eye Nature Source: Author: | Date: 2025-07-15 07:00:00 Source: Author: | Date: 2025-07-15 07:00:00
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye – Nature
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye Nature Source: Author: | Date: 2025-07-04 07:00:00 Source: Author: | Date: 2025-07-04 07:00:00
Sepul Bio Launches Ultevursen Phase 2b Trial for RP
Sepul Bio has announced the dosing of the first patient in the LUNA clinical study, a Phase 2b trial evaluating ultevursen for the treatment of USH2A-associated retinitis pigmentosa (RP). This milestone represents renewed hope for individuals affected by this debilitating…